<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03772756</url>
  </required_header>
  <id_info>
    <org_study_id>2018-139-01</org_study_id>
    <nct_id>NCT03772756</nct_id>
  </id_info>
  <brief_title>EUS-RFA for Unresectable Pancreatic Ductal Adenocarcinoma</brief_title>
  <official_title>Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Unresectable Pancreatic Adenocarcinoma - a Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First People's Hospital of Hangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First People's Hospital of Hangzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the study evaluate the efficacy and safety of EUS-RFA using Habib EUS-RFA catheter with a&#xD;
      prospective randomised trial in patients with inoperable PDAC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The five year survival for pancreatic ductal adenocarcinoma (PDAC) is less than 5% in spite&#xD;
      of the advances in management of cancers in the last few decades. Endobiliary application of&#xD;
      radiofrequency ablation (RFA) has been developed in our unit and used in patients with&#xD;
      unresectable bile duct and pancreatic head adenocarcinomas presenting with biliary&#xD;
      obstruction. Various techniques of EUS-guided tumour ablation have been described, including&#xD;
      RF ablation, photodynamic therapy, laser ablation, and ethanol injection. Endoscopic&#xD;
      ultrasound guided RFA (EUS-RFA) of the pancreatic head using Habib EUS-RFA catheter through a&#xD;
      19-gauge needle was well tolerated in 5 Yucatan pigs and with minimum amount of pancreatitis&#xD;
      .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 20, 2018</start_date>
  <completion_date type="Actual">August 16, 2021</completion_date>
  <primary_completion_date type="Actual">August 16, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in tumour size as measured on EUS and or CT</measure>
    <time_frame>60 days</time_frame>
    <description>The tumor size was compared before and after 60 days EUS-RFA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum levels of Ca 19-9</measure>
    <time_frame>60 days</time_frame>
    <description>Serum levels of Ca 19-9 was compared before and after 60 days EUS-RFA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Survival rate 6 months after EUS-RFA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Survival rate 12 months after EUS-RFA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Pancreatic Adenocarcinoma Non-resectable</condition>
  <arm_group>
    <arm_group_label>EUS-RFA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in EUS-RFA group will undergo endoscopic ultrasound guided radiofrequency ablation(EUS-RFA ) and chemoradiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the control group will receive chemoradiotherapy only</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic ultrasound guided radiofrequency ablation</intervention_name>
    <description>Endoscopic ultrasound guided radiofrequency ablation （EUS-RFA） will be done in 3 different sessions with 2 weeks interval between each session on Day 1, Day 15 and Day 30. Each session will involve multiple applications of EUS-RFA (up to 10) with RF setting of 25 Watts over 90 seconds for each application.</description>
    <arm_group_label>EUS-RFA group</arm_group_label>
    <other_name>EUS-RFA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>chemoradiotherapy</intervention_name>
    <description>Receive chemoradiotherapy</description>
    <arm_group_label>EUS-RFA group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients in the age group 20 to 80 years&#xD;
&#xD;
          -  A cytological or histological diagnosis of inoperable PDAC based on multidisciplinary&#xD;
             review of cross sectional imaging and cytology or histology results.&#xD;
&#xD;
          -  Patients who have been deemed unfit for surgical resection of the PDAC subjects who&#xD;
             are fit for surgical resection but have declined surgery will also be considered for&#xD;
             the study&#xD;
&#xD;
          -  PDAC patients presenting with jaundice to be considered after a successful biliary&#xD;
             drainage&#xD;
&#xD;
          -  Patients ought to be fit enough to be considered for the study (ECOG performance&#xD;
             status 0, 1 or 2)&#xD;
&#xD;
          -  Patients capable of giving informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  ECOG performance status 3 or 4&#xD;
&#xD;
          -  Life expectancy less than 3 months&#xD;
&#xD;
          -  Patients with distant metastases or malignant ascites&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaofeng Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>First People's Hospital of Hangzhou</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jianfeng Yang</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hangzhou First People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>31006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Gaidhane M, Smith I, Ellen K, Gatesman J, Habib N, Foley P, Moskaluk C, Kahaleh M. Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA) of the Pancreas in a Porcine Model. Gastroenterol Res Pract. 2012;2012:431451. doi: 10.1155/2012/431451. Epub 2012 Sep 20.</citation>
    <PMID>23049547</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 9, 2018</study_first_submitted>
  <study_first_submitted_qc>December 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2018</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First People's Hospital of Hangzhou</investigator_affiliation>
    <investigator_full_name>Jianfeng Yang</investigator_full_name>
    <investigator_title>Associate director of gastroenterology department</investigator_title>
  </responsible_party>
  <keyword>pancreatic adenocarcinoma</keyword>
  <keyword>radiofrequency ablation</keyword>
  <keyword>Endoscopic ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

